Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 3—March 2025
Dispatch

Outbreak Caused by Multidrug-Resistant Mycobacterium Tuberculosis with Unusual Combination of Resistance Mutations, Northern Argentina, 2006–2022

Roxana Paul1, Federico Lorenzo1, Beatriz López, María Gabriela Alegre, David Couvin, Nalin Rastogi, Laura Pérez-Lago, Darío García de Viedma, Ana Gamberale, Norma González, Domingo Palmero, Silvia Altabe, Norberto Simboli, and Noemí Kaoru YokoboriComments to Author 
Author affiliation: Instituto Nacional de Enfermedades Infecciosas, ANLIS “Dr. C. G. Malbrán,” Buenos Aires, Argentina (R. Paul, F. Lorenzo, B. López, N. Simboli, N.K. Yokobori); Programa de Control de Tuberculosis, Chaco, Argentina (M.G. Alegre, S. Altabe); Université des Antilles, Guadeloupe, France (D. Couvin); Institut Pasteur de Guadeloupe, Abymes, Guadeloupe (D. Couvin, N. Rastogi); Hospital General Universitario Gregorio Marañón, Madrid, Spain (L. Pérez-Lago, D. García de Viedma); Instituto de Investigaciòn Sanitaria Gregorio Marañón, Madrid (L. Pérez-Lago, D. García de Viedma); Instituto de Salud Carlos III, Madrid (D. García de Viedma); CIBER Enfermedades Respiratorias, Madrid (D. García de Viedma); Hospital Muñiz, Buenos Aires (A. Gamberale, D. Palmero); Instituto Vaccarezza, Buenos Aires (A. Gamberale, D. Palmero); Hospital General de Niños “Pedro de Elizalde,” Buenos Aires (N. González); National Scientific and Technical Research Council, Buenos Aires (N.K. Yokobori)

Main Article

Table 2

Resistance conferring mutations found in Ch strain isolates from patients with MDR-TB infection, Argentina, 2006–2022*

Mutation Drug Confidence grading Phenotype/genotype† Concordance
rpoB_Asp435His
RIF
Associated with resistance–interim
24/24
Yes
rpoB_His445Asp
RIF
Associated with resistance
24/24
Yes
fabG1-inhA_t-8c INH Associated with resistance–interim 24/24 Yes

ETH
Associated with resistance–interim
3/24‡
Partial
katG_Ser315Thr
INH
Associated with resistance
24/24
Yes
embB_Met306Ile
EMB
Associated with resistance
18/24§
Partial
embA_c-11a
EMB
Uncertain significance
NA
NA
pncA_Pro54Leu
PZA
Associated with resistance
24/24
Yes
rpsL_Lys43Arg
STR
Associated with resistance
24/24
Yes
rrs_a1401 g KAN Associated with resistance 1/1 Yes
AMK Associated with resistance 1/1 Yes

CAP
Associated with resistance
1/1
Yes
eis_c-14t KAN Associated with resistance 1/1 Yes
AMK Associated with resistance–interim 0/1 No

CAP
NA
0/1
NA
tlyA_Arg18stop (LoF) KAN NA 0/1 NA
AMK NA 0/1 NA

CAP
Associated with resistance
1/1
Yes
gyrA_Asp94Ala
FLQ
Associated with resistance
10/10¶
Yes
rrl_g2270t
LZD
Associated with resistance–interim
1/1#
Yes
Rv0678_144dupC (LoF) BDQ Associated with resistance 1/1 Yes
CFZ Associated with resistance 1/1** Yes

*Confidence grading according to the World Health Organization Catalogue of Mutations, 2nd Edition (3). AMK, amikacin; BDQ, bedaquiline; CAP, capreomycin; CFZ, clofazimine; EMB, ethambutol; ETH, ethionamide; FLQ, fluoroquinolone; INH, isoniazid; LoF, loss of function; LZD, linezolid; NA, not applicable; PZA, pyrazinamide; RIF, rifampin; Stop, stop codon; STR, streptomycin; 2LI, second-line injectable drugs.†For the isolates studied by whole-genome sequencing; phenotypically resistant isolates/isolates harboring each mutation are indicated. ‡Fifteen isolates were sensitive, 5 isolates had discordant results between methods, and 1 isolate was not tested. §Two isolates were susceptible, 3 had discordant results between proportion and MGIT methods, and 1 isolate was not studied. ¶Resistance to low dose of moxifloxacin. #Isolate 6.4 had a MIC of 4 mg/L for LZD (suggested cutoff value 0.5 mg/L). **Isolate 10.4 had a MIC of 2 mg/L for CFZ (suggested cutoff value 0.25 mg/L). Phenotypic resistance to BDQ was implemented in 2021, and isolate 10.4. was tested in the light of the genomic results.

Main Article

References
  1. Argentina Ministerio de Salud. Boletín N° 7 tuberculosis y lepra en la argentina coordinación de tuberculosis y lepra [cited 2024 Nov 30]. https://www.argentina.gob.ar/sites/default/files/2024/04/boletin_tuberculosis_2024_1642024.pdf
  2. Ritacco  V, López  B, Ambroggi  M, Palmero  D, Salvadores  B, Gravina  E, et al.; National TB Laboratory Network. HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina. Emerg Infect Dis. 2012;18:180210. DOIPubMedGoogle Scholar
  3. World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed. [cited 2024 Nov 30]. https://www.who.int/publications/i/item/9789240082410
  4. Gagneux  S, Long  CD, Small  PM, Van  T, Schoolnik  GK, Bohannan  BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:19446. DOIPubMedGoogle Scholar
  5. Yokobori  N, Paul  R. Informe técnico sobre la tuberculosis multidrogorresistente en la Argentina, 2023 [cited 2024 Nov 30]. https://sgc.anlis.gob.ar/handle/123456789/2618
  6. Monteserin  J, Paul  R, Gravina  E, Reniero  A, Hernandez  T, Mazzeo  E, et al. Genotypic diversity of Mycobacterium tuberculosis in Buenos Aires, Argentina. Infect Genet Evol. 2018;62:17. DOIPubMedGoogle Scholar
  7. Comín  J, Cebollada  A, Ibarz  D, Viñuelas  J, Vitoria  MA, Iglesias  MJ, et al. A whole-genome sequencing study of an X-family tuberculosis outbreak focus on transmission chain along 25 years. Tuberculosis (Edinb). 2021;126:102022. DOIPubMedGoogle Scholar
  8. Bishai  WR, Dannenberg  AM Jr, Parrish  N, Ruiz  R, Chen  P, Zook  BC, et al. Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie’s pulmonary tubercle count method. Infect Immun. 1999;67:49314. DOIPubMedGoogle Scholar

Main Article

1These first authors contributed equally to this article.

Page created: February 04, 2025
Page updated: March 05, 2025
Page reviewed: March 05, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external